Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting

By Bergenstal Richard M.   Garrison Louis P.   Wintle Matthew   Blickensderfer Amy   Wade Rolin   Hou Likun   Miller Lesley-Ann   Scism-Bacon Jamie   Zagar Anthony   Misurski Derek   Herman William H.  

Current Medical Research and Opinion, Vol. 27, Iss. 3, 2011-03 ,pp. : 531-540

Informa Healthcare

Access to resources Recommend Favorite

Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 689-698

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes

By Levin Philip   Wei Wenhui   Wang Li   Pan Chunshen   Douglas Damon   Baser Onur  

Current Medical Research and Opinion, Vol. 28, Iss. 3, 2012-03 ,pp. : 439-446

Informa Healthcare

Access to resources Recommend Favorite

Effectiveness of vildagliptin as add‐on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real‐world setting

By  

JOURNAL OF DIABETES, Vol. 10, Iss. 1, 2018-01 ,pp. : 68-72

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is Exenatide Improving the Treatment of Type 2 Diabetes? Analysis of the Individual Clinical Trials with Exenatide

By  

Reviews on Recent Clinical Trials, Vol. 2, Iss. 1, 2007-01 ,pp. : 77-84

Bentham Science Publishers

Access to resources Recommend Favorite